Clinical trials: Adalimumab
Psoriasis, Cardiovascular Disease
Vascular Inflammation in Psoriasis - Extension Study
VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid…
- Trial name
- VIP-E (NCT01866592)
- Testing
- Adalimumab
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- University of Pennsylvania
Immune System Disorder
Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects
This healthy male volunteers study will evaluate 148 subjects who will receive a single sub-cutaneous dose of HLX03 （a monoclonal antibody against TNF-a, 40 mg/ 0.8 mL） or Adalimumab(Humira,China spourced,40 mg/0.8 mL injection…
- Trial name
- NCT03357939
- Testing
- HLX03, adalimumab
- Where
- China
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Crohn's Disease
Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy
To compare treatment outcome in patients with Crohn's disease with secondary loss of response to infliximab (i.e. initial good response follow by loss of response) treated according to current standards based only on clinical…
- Trial name
- NCT00851565
- Testing
- Measurement of serum infliximab and anti-infliximab antibodies, Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status
- Where
- 8 sites in Denmark
- Volunteers
- 120 people
- Sponsor
- Copenhagen University Hospital at Herlev
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients
One of the main potential causes of these failures of BP therapy response is the development of Anti-drug Anti-body (ADAb) in some patients.
- Trial name
- ABI-RA (NCT02116504)
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psoriatic Arthritis
Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database
This study was a retrospective non-interventional cohort study with secondary use of data from the Medical Data Vision (MDV) hospital-based database.
- Trial name
- FLYWAY (NCT06600009)
- Testing
- Secukinumab, Adalimumab
- Where
- Japan
- Volunteers
- 534 people
- Sponsor
- Novartis
Early Rheumatoid Arthritis
Power Doppler in Hand Joints of Early RA Patients
It is a prospective case-control study with women diagnosed early rheumatoid arthritis. Three therapeutic failures were considered: failure 1 - to the first Disease-modifying antirheumatic drugs (DMARDs) (methotrexate); failure 2…
- Trial name
- NCT04752748
- Testing
- Drug protocol
- Volunteers
- 48 people
- Sponsor
- Federal University of São Paulo
Rheumatoid Arthritis
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
The purpose of this study is to evaluate the efficacy and safety of namilumab in combination with existing methotrexate (MTX) therapy over 24 weeks in participants with moderate to severe early rheumatoid arthritis (RA)…
- Trial name
- TELLUS (NCT02393378)
- Testing
- Namilumab, Adalimumab, Methotrexate
- Where
- 13 sites in Czechia, Estonia and 3 more
- Volunteers
- 7 people
- Sponsor
- Takeda
Crohn's Disease
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
The purpose of this study is to evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in participants with Crohn's disease.
- Trial name
- NCT02185014
- Testing
- Adalimumab
- Volunteers
- 252 people
- Sponsor
- AbbVie
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation
Healthy
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects
This study is to evaluate to compare the pharmacokinetics, safety, tolerability, and immunogenicity of two formulations of SB5 in healthy male subjects.
- Trial name
- NCT04514796
- Testing
- Adalimumab
- Where
- Germany
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Samsung Bioepis Co., Ltd.
Psoriatic Arthritis
Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine
Safety and effectiveness, quality of life and work productivity of Humira in patients with psoriatic arthritis in clinical routine.
- Trial name
- ELAN (NCT01078610)
- Testing
- adalimumab (Humira)
- Sponsor
- Abbott
Uveitis
An Interventional Study of Upadacitinib Extended-Release Tablets in Patients With Refractory Uveitis
Upadacitinib sustained-release tablets have not yet been approved for the treatment of uveitis. The current use falls under the category of "off-label medication", which means providing patients with potentially beneficial…
- Trial name
- NCT07773623
- Testing
- Upadacitinib Extended-Release Tablets
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Arthritis; Behcet
Efficacy of Humira in Behcet Patients With Arthritis
Hypothesis - Behcet's disease is a multisystemic chronic relapsing inflammatory disease, classified among the vasculitides. The clinical manifestations include mucocutaneous lesions, articular, ocular, vascular, gastrointestinal…
- Trial name
- NCT01497717
- Testing
- Adalimumab (Humira)
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Rambam Health Care Campus
Psoriasis
Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis
Vitamins modulating homocysteine affect both TNF-alpha, vascular endothelial growth factor, and theoretically enhance the anti-inflammatory version of NOS thus hopefully increasing the efficacy and reducing the chance of some…
- Trial name
- NCT01704599
- Testing
- Humira Then Humira plus 3 B vitamins
- Volunteers
- 8 people
- Sponsor
- Wayne State University
Psoriasis Vulgaris
Dose Tapering Study of Adalimumab in Psoriasis
The optimal therapeutic serum trough level (Ctrough) of adalimumab was defined between 3,5 and 7,0 µg/ml in patients with plaque type psoriasis. An adalimumab Ctrough above this therapeutic range did not add clinical response.
- Trial name
- NCT04028713
- Testing
- Venapuncture, Dried blood spot, Dose reduction
- Where
- 7 sites in Belgium
- Volunteers
- 19 people
- Sponsor
- University Hospital, Ghent
Ulcerative Colitis
In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis
Molecular imaging with infliximab antibody with FITC has the potential to predict therapeutic responses to infliximab antibody and can be used for personalized medicine in ulcerative colitis.
- Trial name
- NCT02852850
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong University
Ankylosing Spondylitis (AS), Psoriasis
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.
- Conditions
- Ankylosing Spondylitis (AS), Psoriasis, Rheumatoid Arthritis (RA)
- Trial name
- ADMIT (NCT03339089)
- Where
- 10 sites in China
- Volunteers
- 224 people
- Sponsor
- AbbVie
Ulcerative Colitis, Thromboembolism
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
Post-authorization, prospective and unicenter clinical trial, in which patients with UC will be included. The treatment with anti-TNFα (infliximab, adalimumab or golimumab) or JAK-inhibitors (tofacitinib) will be initiated by…
- Trial name
- NCT05313620
- Testing
- Tofacitinib, Infliximab Adalimumab y Golimumab
- Where
- Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Rheumatoid Arthritis (RA)
Optimization of Treatment With Adalimumab (Humira)
The purpose of this trial is to assess the effect of two Intensive Outpatient Management Strategies (IOMS) versus Routine Care (RC) on the outcomes of patients with Rheumatoid Arthritis (RA) that are treated with adalimumab.
- Trial name
- NCT01585064
- Testing
- DAS28-IOMS, 0SJ-IOMS, Routine Care (RC)
- Where
- Canada
- Volunteers
- 309 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Psoriasis, Psoriatic-arthritis
PsoBest - The German Psoriasis Registry
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.
- Trial name
- NCT01848028
- Where
- Germany
- Volunteers
- 3,500 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf